Events & Presentations

Upcoming Webcasts

  • uniQure’s Virtual Research & Development Event
    8:30AM ET to 10:30 AM ET

    View Webcast

Webcast Archive

  • Stifel 2022 Healthcare Conference
    Fireside chat: 8:35AM ET to 9:05AM ET

    View Webcast
  • Chardan's 6th Annual Genetic Medicines Conference
    8:30 a.m ET/ 2:30 p.m. CET

    View Webcast
  • Jefferies Cell and Genetic Medicines Summit
    2:30 p.m. ET / 8:30 p.m. CET

    View Webcast

Investor Presentations

  • AMT-130 12-Month Low-Dose Cohort Update – Investor Webcast Presentation

    View Presentation
  • ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions

    View Presentation
  • ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders

    View Presentation
  • ESGCT 2022 – AAV-miQURE®-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse models

    View Presentation
  • ESGCT 2022 – Overexpressing a protective variant while simultaneously lowering toxic APOE as potential treatment for Alzheimer Disease

    View Presentation
  • ESGCT 2022 – Development of a novel AAV9 gene therapy for the treatment of temporal lobe epilepsy using animal model and human organotypic slices

    View Presentation
  • ESGCT 2022 – Biodistribution and safety of a novel AAV9 gene therapy for treatment of temporal lobe epilepsy shown in non-human primates

    View Presentation
  • ESGCT 2022 – Scale-down of AAV production from commercial scale to a high-throughput mini-bioreactor system

    View Presentation
  • ESGCT 2022 – Impact of bioreactor control parameters on AAV production

    View Presentation
  • EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B

    View Presentation
  • ISTH 2021 – Clinical Outcomes in Adults with Hemophilia B With Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the HOPE-B Trial

    View Presentation
  • Gene Therapy Information

    View Presentation
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button